Combining Organoid Models with Next-Generation Sequencing to Reveal Tumor Heterogeneity and Predict Therapeutic Response in Breast Cancer

Figure 4

Breast cancer organoids reflect the clinical response and genetic prediction. (a) Variation landscape of the patient’s PIK3CA and TP53 genes (46). (b) The gene mutation-related medication impact from the GDSC database is displayed as a scatter plot. (c) Assessment of PDOs, NGS-based prediction, and clinical response. The pharmacological responses for sensitivity, unclear, and resistance are colored in green, gray, and red, respectively.

(a)

(b)

(c)